Retatrutide 20mg research vial
Retatrutide is a lab-made peptide that acts on three hormone receptors at once; one 20mg vial costs 2,600,000 VND ($102 USD). Its price was confirmed on 11 October 2026, and the three trial papers below each carry a PubMed link. Retatrutide is still in clinical trials. The newest papers here call it an investigational compound, not an approved medicine. The vial sold here has no approval for use in people.
What is Retatrutide?
The three receptors are for the hormones GIP, GLP-1 and glucagon.
The newest papers describe retatrutide as still in clinical trials.
Good to know
Each retatrutide trial below is told by its design, its people and its measures. None of it is a medical use, and nothing here suggests one.
Retatrutide in phase 2 trials, 2023 to 2024
- Human trial, 2023. A phase 2 trial in 338 adults with obesity, or overweight plus a weight-related condition, measured weight change over 48 weeks against a placebo.
- Human trial, 2023. A phase 2 trial in 281 adults with type 2 diabetes measured blood sugar and body weight over 36 weeks. It compared retatrutide with a placebo and with dulaglutide, an older medicine in the same family.
- Human trial substudy, 2024. A smaller study inside the 2023 obesity trial listed first. It measured liver fat in 98 adults with obesity and fatty liver, against a placebo.
Retatrutide has large human trials, and phase 3 papers have started to appear. One 2026 phase 3 trial ran at 48 sites in the USA, Mexico and India. It enrolled 537 adults whose type 2 diabetes diet and exercise had not brought under control. It was randomized and double-blind, with a placebo group. Over 40 weeks its main measure was the change in HbA1c, a long-term blood sugar marker. It also tracked body weight and side effects.
How to read this
Retatrutide sits at the opposite end from most peptides here: big, randomized trials with placebo groups, each one in a defined group of adults and in a trial setting. The 2024 liver paper is a substudy of the 2023 obesity trial, not a separate trial, so count papers, not trials. The trials ran for 36 to 48 weeks, and phase 3 papers are only starting to come out. No trial listed here used vials sold by this store, so none of them describes what is in this vial.
Sources: PubMed record 37366315 (human trial, 2023); PubMed record 37385280 (human trial, 2023); PubMed record 38858523 (human trial substudy, 2024); PubMed record 42250575 (2026 phase 3 trial).
How much does Retatrutide cost per pack?
| Pack | Price | Per vial | Per mg |
|---|---|---|---|
| 1 vial | 2,600,000 VND ($102 USD) | 2,600,000 VND ($102 USD) | 130,000 VND ($5.10 USD) |
| 3 vials | 6,318,000 VND ($247.86 USD) | 2,106,000 VND ($82.62 USD) | 105,300 VND ($4.13 USD) |
| 5 vials | 9,360,000 VND ($367.20 USD) | 1,872,000 VND ($73.44 USD) | 93,600 VND ($3.67 USD) |
| 10 vials | 15,600,000 VND ($612 USD) | 1,560,000 VND ($61.20 USD) | 78,000 VND ($3.06 USD) |
Questions about Retatrutide
What has research on Retatrutide looked at?
Large human trials in adults with obesity or type 2 diabetes, plus a fatty liver substudy of the obesity trial. Phase 3 papers have started to appear.
Which receptors does retatrutide act on?
Three: the receptors for GIP, GLP-1 and glucagon, hormones that help control blood sugar, appetite and energy use. Tirzepatide, next to it on the shelf, acts on two of them.
How much has been published on retatrutide?
205 PubMed records by 18 October 2026, when we searched, and it is still in clinical trials. The 2024 liver fat paper on this page is a substudy of the 2023 obesity trial, so we count papers, not separate trials.
By Peptides Ho Chi Minh, 11 October 2026